BROOKS vs WINDLAS: Stock Comparison

Brooks Laboratories Limited vs Windlas Biotech LtdUpdated 16 Apr 26, 4:01 PM ISTNSE & company filings

Windlas Biotech Ltd is the larger company by market capitalisation. Brooks Laboratories Limited shows a lower P/E, a higher ROE and a higher net margin, while Windlas Biotech Ltd shows a higher dividend yield, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BROOKS leads 7; WINDLAS leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BROOKSWINDLAS

Valuation lens

What price are you paying?

Market CapContext only
₹182 Cr
₹2,050 Cr
P/E RatioBROOKS has the lower reading
8.22x
42.91x
P/B RatioBROOKS has the lower reading
1.65x
3.61x
EPSWINDLAS has the higher reading
₹7.32
₹31.5
Book ValueContext only
₹33.3
₹275
Dividend YieldWINDLAS has the higher reading
0%
0.63%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WINDLAS is the larger company
₹2,050 Cr vs ₹182 Cr
P/E Ratio
BROOKS has a lower P/E
8.22x vs 42.91x
P/B Ratio
BROOKS has a lower P/B
1.65x vs 3.61x
EPS
WINDLAS has higher earnings per share
₹31.5 vs ₹7.32
Dividend Yield
WINDLAS has a higher dividend yield
0.63% vs 0%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs -6.37%
EPS Growth (TTM YoY)
BROOKS has faster EPS growth
0% vs -2.6%
Qtr Sales Growth
BROOKS has stronger quarterly sales growth
42.3% vs 17.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBROOKSWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBROOKSWINDLAS
Live Price₹69.58₹993.6
Day Change-3.45%0.55%
Volume91,9991.73 L
52-Week High₹163.9₹1,045.45
52-Week Low₹36.3₹697.4
Distance from 52W High-57.55%-4.96%

Valuation

MetricBROOKSWINDLAS
Market Cap₹182 Cr₹2,050 Cr
P/E Ratio8.22x42.91x
P/B Ratio1.65x3.61x
EPS₹7.32₹31.5
Book Value₹33.3₹275
Dividend Yield0%0.63%

Growth

MetricBROOKSWINDLAS
Revenue Growth (TTM YoY)-6.37%17.7%
EPS Growth (TTM YoY)0%-2.6%
Qtr Sales Growth42.3%17.7%
Qtr Profit Growth498%-1.78%

Profitability & Leverage

MetricBROOKSWINDLAS
ROE20.04%12.2%
ROCE-9.93%15.9%
Net Margin28.67%7.35%
Operating Margin7.74%11.6%
Debt to Equity0.06x0.06x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBROOKSWINDLAS
Promoter Holding52.62%63.31% 1.41 pp
FII Holding0% 0.17 pp2.04% 1.44 pp
DII Holding10.38%9.84% 1.97 pp
Public Holding37% 0.16 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Brooks Laboratories Limited and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.